DailyStocks Stock Article Search

https://seekingalpha.com/article/4673481-teva-alvotech-simlandi-approval-opens-new-generic-market-opportunities?source=feed_tag_israel Feb 26, 2024 - Teva's stock has risen 32% since December, outperforming the SPY, buoyed by FDA approval of Simlandi, a biosimilar to Humira. Learn more about TEVA stock here. 0

https://seekingalpha.com/news/4077679-teva-stock-upgraded-jp-morgan-catalysts?source=feed_tag_israel Mar 08, 2024 - Teva Pharmaceutical (TEVA) receives an upgrade from J.P. Morgan, on upcoming positive catalysts as the bank reviews its specialty pharma coverage. Read more here. 0

https://seekingalpha.com/news/4087243-teva-and-mabxience-sign-global-licensing-agreement-for-oncology-biosimilar-candidate?source=feed_tag_israel Apr 04, 2024 - Teva Pharmaceuticals and mAbxience have signed a strategic licensing agreement to develop a biosimilar treatment for multiple oncology indications,... 0

https://seekingalpha.com/news/4091382-alvotech-signs-u-s-agreement-to-expand-access-for-newly-approved-high-concentration?source=feed_sector_healthcare Apr 19, 2024 - Alvotech (ALVO) in agreement with Teva Pharmaceuticals (TEVA), signed a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryv in US market. 0

https://www.zacks.com/stock/news/2204522/corcept-cort-falls-on-loss-of-korlym-patent-lawsuit-to-teva?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2204522 Jan 02, 2024 - The United States district court for the district of New Jersey rules against Corcept (CORT) in a patent infringement lawsuit against Teva Pharmaceuticals. Stock declines. 0

https://www.zacks.com/stock/news/2216435/unveiling-teva-pharmaceutical-industries-ltd-teva-q4-outlook-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2216435 Jan 26, 2024 - Besides Wall Street's top -and-bottom-line estimates for Teva Pharmaceutical Industries Ltd. (TEVA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023. 0

https://www.zacks.com/stock/news/2218858/teva-pharmaceutical-industries-ltd-teva-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2218858 Jan 31, 2024 - Although the revenue and EPS for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. 0

https://www.zacks.com/stock/news/2245567/will-corcept-cort-bank-on-korlym-in-2024-amid-stiff-rivalry?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245567 Mar 25, 2024 - Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition. 0

https://www.zacks.com/commentary/2257822/3-generic-drug-stocks-to-watch-amid-challenging-market-prospects?cid=CS-ZC-FT-industry_outlook-2257822 Apr 18, 2024 - The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS. 0

https://seekingalpha.com/article/4654636-teva-pharmaceutical-industries-limited-teva-presents-6th-annual-evercore-isi-healthconx?source=feed_tag_israel Nov 28, 2023 - 0